Abstract:BACKGROUND: 19F-MRI and 19F-MRS can identify specific cell types after in-vitro or in-vivo 19F-labeling. Knowledge on the potential to track in-vitro 19F-labeled immune cells in tumor models by 19F-MRI/MRS is scarce.AIM: To study 19F-based MR techniques for in-vivo tracking of adoptively transferred immune cells after in-vitro 19F-labeling, i.e. to detect and monitor their migration non-invasively in melanoma-bearing mice.METHODS: Splenocytes (SP) were labeled in-vitro with a perfluorocarbon (PFC) and IV-injected into non-tumor bearing mice. In-vitro PFC-labeled ovalbumin (OVA)-specific T cells from the T cell receptor-transgenic line OT-1, activated with anti-CD3 and anti-CD28 antibodies (Tact) or OVA-peptide pulsed antigen presenting cells (TOVA-act), were injected into B16 OVA melanoma-bearing mice. The distribution of the 19F-labelled donor cells was determined in-vivo by 19F-MRI/MRS. In-vivo 19F-MRI/MRS results were confirmed by ex-vivo 19F-NMR and flow cytometry.RESULTS: SP, Tact, and TOVA-act were successfully PFC-labeled in-vitro yielding 3x1011-1.4x1012 19F-atoms/cell in the 3 groups. Adoptively transferred 19F-labeled SP, TOVA-act, and Tact were detected by coil-localized 19F-MRS in the chest, abdomen, and left flank in most animals (corresponding to lungs, livers, and spleens, respectively, with highest signal-to-noise for SP vs TOVA-act and Tact, p<0.009 for both). SP and Tact were successfully imaged by 19F-MRI (n = 3; liver). These in-vivo data were confirmed by ex-vivo high-resolution 19F-NMR-spectroscopy. By flow cytometric analysis, however, TOVA-act tended to be more abundant versus SP and Tact (liver: p = 0.1313; lungs: p = 0.1073; spleen: p = 0.109). Unlike 19F-MRI/MRS, flow cytometry also identified transferred immune cells (SP, Tact, and TOVA-act) in the tumors.CONCLUSION: SP, Tact, and TOVA-act were successfully PFC-labeled in-vitro and detected in-vivo by non-invasive 19F-MRS/MRI in liver, lung, and spleen. The portion of 19F-labeled T cells in the adoptively transferred cell populations was insufficient for 19F-MRS/MRI detection in the tumor. While OVA-peptide-activated T cells (TOVA-act) showed highest infiltration into all organs, SP were detected more reliably by 19F-MRS/MRI, most likely explained by cell division of TOVA-act after injection, which dilutes the 19F content in the T cell-infiltrated organs. Non-dividing 19F-labeled cell species appear most promising to be tracked by 19F-MRS/MRI.

Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer

Clinical cell therapy imaging using a perfluorocarbon tracer and fluorine-19 MRI

Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging

Method for estimation of apoptotic cell fraction of cytotherapy using in vivo fluorine-19 magnetic resonance: pilot study in a patient with head and neck carcinoma receiving tumor-infiltrating lymphocytes labeled with perfluorocarbon nanoemulsion

In vivo imaging platform for tracking immunotherapeutic cells

In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI

Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection

Bio-orthogonal Metabolic Fluorine Labeling Enables Deep-Tissue Visualization of Tumor Cells in Vivo by 19F Magnetic Resonance Imaging.

Quantitative Magnetic Resonance Fluorine Imaging: Today and Tomorrow

19Fluorine‐MRI Based Longitudinal Immuno‐Microenvironment‐Monitoring for Pancreatic Cancer

<SUP>19</SUP>F MRI-fluorescence imaging dual-modal cell tracking with partially fluorinated nanoemulsions

Perfluorocarbons-Based 19F Magnetic Resonance Imaging in Biomedicine

Systems Engineering Approach Towards Sensitive Cellular Fluorine‐19 MRI

A stable, highly concentrated fluorous nanoemulsion formulation for in vivo cancer imaging via 19F‐MRI

Molecular Imaging for Cancer Immunotherapy: Seeing is Believing

Nanotechnology as a Versatile Tool for 19F-MRI Agent’s Formulation: A Glimpse into the Use of Perfluorinated and Fluorinated Compounds in Nanoparticles

Glycan Metabolic Fluorine Labeling for in Vivo Visualization of Tumor Cells and in Situ Assessment of Glycosylation Variations.

Cationic fluorinated micelles for cell labeling and 19F-MR imaging

Partially Fluorinated Nanoemulsions for 19F MRI-fluorescence Dual Imaging Cell Tracking.

Hydrofluorocarbon Nanoparticles for 19F MRI-fluorescence Dual Imaging and Chemo-Photodynamic Therapy

Self‐assembled Fluorinated Nanoparticles as Sensitive and Biocompatible Theranostic Platforms for 19f Mri